Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate if the combination of psoralen plus ultraviolet A and narrowband ultraviolet B is more effective than narrowband ultraviolet B alone in the treatment of vitiligo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NB-UVB phototherapy | Placebo Comparator | NB-UVB alone |
|
| phototherapy and photochemotherapy | Experimental | NB-UVB and PUVA |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Phototherapy | Other |
| ||
| Phototherapy and Photochemotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| Determine the quantity of repigmentation | Determination the degree of repigmentation measured by the VASI score (Vitiligo area Scoring Index) after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Determine the quality of repigmentation. | Determination of the color of repigmentation, pattern of repigmentation, and the cessation of spread of vitiligo after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone. | Study initiation, 3 months and 6 months. |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Iltefat Hamzavi, MD | Henry Ford Dermatology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Henry Ford Dermatology | Detroit | Michigan | 48202 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Feb 16, 2022 | |
| Reset | Apr 26, 2022 | |
| Release | Jun 14, 2023 | |
| Reset | Feb 2, 2024 | |
| Release | Oct 7, 2024 | |
| Reset | Nov 20, 2024 | |
| Release | Feb 13, 2025 | |
| Reset | Feb 14, 2025 | |
| Release | May 21, 2026 | |
| Reset | May 21, 2026 | |
| Release | Jun 4, 2026 | |
| Reset | Jun 29, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Feb 16, 2022 | Apr 26, 2022 | |||
| Jun 14, 2023 |
| ID | Term |
|---|---|
| D014820 | Vitiligo |
| ID | Term |
|---|---|
| D017496 | Hypopigmentation |
| D010859 | Pigmentation Disorders |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D010789 | Phototherapy |
| D010778 | Photochemotherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D003131 | Combined Modality Therapy |
| D004358 | Drug Therapy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
|
| Feb 2, 2024 |
| Oct 7, 2024 | Nov 20, 2024 |
| Feb 13, 2025 | Feb 14, 2025 |
| May 21, 2026 | May 21, 2026 |
| Jun 4, 2026 | Jun 29, 2026 |